5/29
04:05 pm
imrx
Immuneering to Present at the Jefferies Global Healthcare Conference
Medium
Report
Immuneering to Present at the Jefferies Global Healthcare Conference
5/8
08:08 am
imrx
Immuneering Co. (NASDAQ: IMRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $15.00 price target on the stock.
Medium
Report
Immuneering Co. (NASDAQ: IMRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $15.00 price target on the stock.
5/7
04:19 pm
imrx
Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates [Yahoo! Finance]
Medium
Report
Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates [Yahoo! Finance]
5/7
04:05 pm
imrx
Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
Medium
Report
Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
5/7
09:32 am
imrx
We Think Immuneering (NASDAQ:IMRX) Needs To Drive Business Growth Carefully [Yahoo! Finance]
Low
Report
We Think Immuneering (NASDAQ:IMRX) Needs To Drive Business Growth Carefully [Yahoo! Finance]
5/6
04:34 pm
imrx
Immuneering Recognizes Melanoma Awareness Month [Yahoo! Finance]
Medium
Report
Immuneering Recognizes Melanoma Awareness Month [Yahoo! Finance]
5/6
04:30 pm
imrx
Immuneering Recognizes Melanoma Awareness Month
Medium
Report
Immuneering Recognizes Melanoma Awareness Month
4/12
08:00 am
imrx
Immuneering Co. (NASDAQ: IMRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $15.00 price target on the stock.
Low
Report
Immuneering Co. (NASDAQ: IMRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $15.00 price target on the stock.
4/9
12:04 pm
imrx
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models [Yahoo! Finance]
Low
Report
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models [Yahoo! Finance]
4/9
12:00 pm
imrx
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
Medium
Report
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
4/3
04:05 pm
imrx
Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Low
Report
Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference
4/2
08:10 am
imrx
Immuneering Co. (NASDAQ: IMRX) had its price target lowered by analysts at Mizuho from $20.00 to $8.00. They now have a "buy" rating on the stock.
High
Report
Immuneering Co. (NASDAQ: IMRX) had its price target lowered by analysts at Mizuho from $20.00 to $8.00. They now have a "buy" rating on the stock.
3/27
08:21 am
imrx
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations [Yahoo! Finance]
Low
Report
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations [Yahoo! Finance]
3/27
08:00 am
imrx
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
Low
Report
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
3/21
07:06 am
imrx
Immuneering Director Acquires 7.5% More Stock [Yahoo! Finance]
Low
Report
Immuneering Director Acquires 7.5% More Stock [Yahoo! Finance]
3/19
02:27 am
imrx
Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone [Seeking Alpha]
Low
Report
Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone [Seeking Alpha]
3/18
04:16 pm
imrx
Immuneering stock rebounds 34% following last week's selloff [Seeking Alpha]
Low
Report
Immuneering stock rebounds 34% following last week's selloff [Seeking Alpha]
3/18
03:05 pm
imrx
Immuneering Co. (NASDAQ: IMRX) had its "neutral" rating re-affirmed by analysts at Guggenheim.
Medium
Report
Immuneering Co. (NASDAQ: IMRX) had its "neutral" rating re-affirmed by analysts at Guggenheim.
3/18
12:57 pm
imrx
Immuneering (IMRX) Plummets 71% in One Week: Here's Why [Yahoo! Finance]
Low
Report
Immuneering (IMRX) Plummets 71% in One Week: Here's Why [Yahoo! Finance]
3/15
10:07 am
imrx
Geron, Graphite Bio, Immuneering among healthcare movers [Seeking Alpha]
High
Report
Geron, Graphite Bio, Immuneering among healthcare movers [Seeking Alpha]
3/15
08:08 am
imrx
Immuneering Co. (NASDAQ: IMRX) had its price target lowered by analysts at Needham & Company LLC from $20.00 to $15.00. They now have a "buy" rating on the stock.
High
Report
Immuneering Co. (NASDAQ: IMRX) had its price target lowered by analysts at Needham & Company LLC from $20.00 to $15.00. They now have a "buy" rating on the stock.
3/15
07:44 am
imrx
Immuneering Co. (NASDAQ: IMRX) was downgraded by analysts at TD Cowen from an "outperform" rating to a "market perform" rating.
High
Report
Immuneering Co. (NASDAQ: IMRX) was downgraded by analysts at TD Cowen from an "outperform" rating to a "market perform" rating.
3/15
07:44 am
imrx
Immuneering Co. (NASDAQ: IMRX) was downgraded by analysts at Jefferies Financial Group Inc. from a "buy" rating to a "hold" rating. They now have a $3.00 price target on the stock, down previously from $16.00.
High
Report
Immuneering Co. (NASDAQ: IMRX) was downgraded by analysts at Jefferies Financial Group Inc. from a "buy" rating to a "hold" rating. They now have a $3.00 price target on the stock, down previously from $16.00.
3/14
07:18 am
imrx
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors [Yahoo! Finance]
High
Report
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors [Yahoo! Finance]
3/14
07:00 am
imrx
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors
High
Report
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors